Enzychem Lifesciences Corporation
Enzychem Lifesciences Corporation operates in Diversified Metals & Mining.
Enzychem Lifesciences Corporation (183490) - Total Assets
Latest total assets as of June 2024: ₩195.14 Billion KRW
Based on the latest financial reports, Enzychem Lifesciences Corporation (183490) holds total assets worth ₩195.14 Billion KRW as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Enzychem Lifesciences Corporation - Total Assets Trend (2016–2023)
This chart illustrates how Enzychem Lifesciences Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Enzychem Lifesciences Corporation - Asset Composition Analysis
Current Asset Composition (December 2023)
Enzychem Lifesciences Corporation's total assets of ₩195.14 Billion consist of 82.5% current assets and 17.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.3% |
| Accounts Receivable | ₩11.63 Billion | 5.5% |
| Inventory | ₩14.95 Billion | 7.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩4.37 Billion | 2.1% |
| Goodwill | ₩1.48 Billion | 0.7% |
Asset Composition Trend (2016–2023)
This chart illustrates how Enzychem Lifesciences Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enzychem Lifesciences Corporation's current assets represent 82.5% of total assets in 2023, an increase from 69.1% in 2016.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2023, down from 22.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 7.1% of total assets.
Enzychem Lifesciences Corporation Competitors by Total Assets
Key competitors of Enzychem Lifesciences Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
Enzychem Lifesciences Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Enzychem Lifesciences Corporation generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Enzychem Lifesciences Corporation is currently not profitable relative to its asset base.
Enzychem Lifesciences Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.43 | 16.04 | 7.39 |
| Quick Ratio | 14.43 | 14.80 | 6.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩149.73 Billion | ₩ 166.50 Billion | ₩ 51.04 Billion |
Enzychem Lifesciences Corporation - Advanced Valuation Insights
This section examines the relationship between Enzychem Lifesciences Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -14.5% |
| Total Assets | ₩211.55 Billion |
| Market Capitalization | $7.37K USD |
Valuation Analysis
Below Book Valuation: The market values Enzychem Lifesciences Corporation's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Enzychem Lifesciences Corporation's assets decreased by 14.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enzychem Lifesciences Corporation (2016–2023)
The table below shows the annual total assets of Enzychem Lifesciences Corporation from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | ₩211.55 Billion | -14.55% |
| 2022-12-31 | ₩247.55 Billion | +86.01% |
| 2021-12-31 | ₩133.08 Billion | +7.50% |
| 2020-12-31 | ₩123.80 Billion | +45.66% |
| 2019-12-31 | ₩84.99 Billion | +26.77% |
| 2018-12-31 | ₩67.05 Billion | +82.17% |
| 2017-12-31 | ₩36.80 Billion | +0.37% |
| 2016-12-31 | ₩36.67 Billion | -- |